Rivaroxaban , ≥99% , 366789-02-8

CAS NO.：366789-02-8

Empirical Formula: C19H18ClN3O5S

Molecular Weight: 435.88

MDL number: MFCD11974010

EINECS: 685-132-2

PRODUCT Properties

• Melting point: 228-229°C
• Boiling point: 732.6±60.0 °C(Predicted)
• Density: 1.460±0.06 g/cm3(Predicted)
• storage temp.: Inert atmosphere,2-8°C
• solubility: insoluble in H2O; insoluble in EtOH; ≥13.9 mg/mL in DMSO with gentle warming
• form: solid
• pka: 13.36±0.46(Predicted)
• color: White to off-white
• InChI: InChI=1S/C19H18ClN3O5S/c20-16-6-5-15(29-16)18(25)21-9-14-10-23(19(26)28-14)13-3-1-12(2-4-13)22-7-8-27-11-17(22)24/h1-6,14H,7-11H2,(H,21,25)/t14-/m0/s1
• InChIKey: KGFYHTZWPPHNLQ-AWEZNQCLSA-N
• SMILES: C1(C(NC[C@@H]2OC(=O)N(C3=CC=C(N4CCOCC4=O)C=C3)C2)=O)SC(Cl)=CC=1

Description and Uses

Rivaroxaban is an orally active, direct inhibitor of Factor Xa (Ki = 0.4 nM), which is a crucial component of the intrinsic and extrinsic pathways of the blood coagulation cascade. It demonstrates >10,000-fold greater selectivity for Factor Xa compared to other related serine proteases (thrombin, trypsin, plasmin, FVIIa, FIXa, FXIa, urokinase, and activated protein C). In various animal arterial and venous thrombosis models, rivaroxaban is reported to inhibit thrombin formation without prolonging bleeding time and has been approved for clinical use as an anticoagulant in the prevention of stroke and the treatment of venous thromboembolisms.

Rivaroxaban is a novel antithrombotic agent. It is a novel, oral, selective direct inhibitor of factor Xa developed by Bayer Healthcare. It has been approved by the EMEA and FDA for the prevention ofvenous thromboembolism in adult patients after total hip replacement or total kneereplacement surgery.

Safety

• Symbol(GHS): GHS09
• Hazard statements: H411